Modell för strukturerad introduktion av nya läkemedel. Syftet är att erbjuda alla patienter ändamålsenlig behandling
Sammanfattning
The drug market is rapidly changing. Many biotechnological drugs are introduced in healthcare. These medicines are expensive, some offer benefits for the patients while the efficacy and safety of others is uncertain. It is essential that society can afford to offer all patients effective treatment. Consequently, new drugs should be introduced systematically. The metropolitan health region in Stockholm, Sweden, has established a structured model for the introduction of new drugs into clinical practice. The model comprises early detection of pipeline drugs (horizon scanning), forecasting on drug expenditures, critical drug evaluation, and structured protocols for the introduction of new medicines which allows evaluations of their effect, safety and cost-effectiveness. A substantial increase of costs for drug therapy is forecasted for 2008 and 2009 (8,6 % and 7,4 %, respectively, corresponding to approx. 500 million SEK annually).